Foresite Capital Management IV, LLC bought $1000k of EIKN
owner at Eikon Therapeutics, Inc.. 55,555 shares at an average of $18.00, traded Feb 4, 2026, filed Feb 6, 2026.
Score components
- +12Role10% owner
- +25Trade size$1000k at market
- 0Relative to holdingsHoldings up 4.4%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.8%, 3m -31.3%, 6m -35.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-26-011662, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +1,340,878 | $0.00 | $0 | 1,340,878 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +335,521 | $0.00 | $0 | 1,676,399 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +37,855 | $0.00 | $0 | 1,714,254 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +229,428 | $0.00 | $0 | 1,943,682 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +697,885 | $0.00 | $0 | 697,885 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +37,855 | $0.00 | $0 | 735,740 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +1,626 | $0.00 | $0 | 737,366 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +67,207 | $0.00 | $0 | 804,573 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +458,855 | $0.00 | $0 | 1,263,428 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +348,942 | $0.00 | $0 | 348,942 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +37,855 | $0.00 | $0 | 386,797 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +922 | $0.00 | $0 | 387,719 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +38,133 | $0.00 | $0 | 425,852 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Common Stockindirect: See Footnote | +408,725 | $0.00 | $0 | 408,725 | Feb 6, 2026 |
| Feb 4, 2026 | POpen-market purchase Common Stockindirect: See Footnote | +55,555 | $18.00 | $1000k | 1,318,983 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series A Preferred Stockderivativeindirect: See Footnote | -10,000,000 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series A-1 Preferred Stockderivativeindirect: See Footnote | -2,502,252 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series A-1 Preferred Stockderivativeindirect: See Footnote | -5,204,684 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series A-1 Preferred Stockderivativeindirect: See Footnote | -2,602,342 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series B-1 Preferred Stockderivativeindirect: See Footnote | -282,317 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series B-1 Preferred Stockderivativeindirect: See Footnote | -282,317 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series B-1 Preferred Stockderivativeindirect: See Footnote | -282,317 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series B-1 Preferred Stockderivativeindirect: See Footnote | -3,048,192 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series C Preferred Stockderivativeindirect: See Footnote | -12,123 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series C Preferred Stockderivativeindirect: See Footnote | -6,878 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series C-1 Preferred Stockderivativeindirect: See Footnote | -501,219 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series C-1 Preferred Stockderivativeindirect: See Footnote | -284,392 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series D Preferred Stockderivativeindirect: See Footnote | -1,711,025 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | CConversion Series D Preferred Stockderivativeindirect: See Footnote | -3,422,051 | $0.00 | $0 | 0 | Feb 6, 2026 |
Related signals
Other insiders at Eikon Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | EIKNbuy Eikon Therapeutics, Inc. | Column Group IV GP, LP owner | $1.0M 89,200 shares | - | |
| 67Notable | Eikon Therapeutics, Inc. | Column Group IV GP, LP owner | $38M 2,117,760 shares | +74% | |
| 63Notable | Eikon Therapeutics, Inc. | Josh Wolfe director, owner | $5.0M 277,776 shares | - | |
| 63Notable | Eikon Therapeutics, Inc. | Josh Wolfe director, owner | $5.0M 277,776 shares | - | |
| 63Notable | Eikon Therapeutics, Inc. | Kenneth C Frazier director | $2.0M 111,111 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.